Basati Gholam, Razavi Amirnader Emami, Pakzad Iraj, Malayeri Fardin Ali
Department of Clinical Biochemistry, Faculty of Allied Medical Sciences, Ilam University of Medical Science, Ilam, Iran.
Iran National Tumor Bank, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Tumour Biol. 2016 Feb;37(2):1781-8. doi: 10.1007/s13277-015-3967-0. Epub 2015 Aug 29.
The microRNAs (miRNAs), miR-194 and miR-29b, have been shown to downregulate in colorectal cancer (CRC) and may identify and classify CRC patients as compared with those in control subjects. In the current study, we aimed to explore whether the serum levels of the miRNAs could be potential biomarkers for diagnosis and prognosis of CRC. A quantitative reverse-transcription polymerase chain reaction (qRT-PCR) assay was utilized to determine and compare serum levels of miR-194 and miR-29b in 55 patients with CRC and 55 control subjects. The correlations between levels of the miRNAs and clinicopathological stages of cancer were analyzed in patients. Receiver operating characteristic (ROC) curve and survival analyses were carried out, respectively, to determine diagnostic and prognostic values of the miRNAs. Serum levels of miR-194 and miR-29b were found to be significantly lower in CRC patients than those in control subjects (P < 0.0001). Moreover, serum levels of the miRNAs in patients were inversely correlated with the advanced TNM stages (P = 0.01). ROC curve and survival analyses revealed that reduced levels of the miRNAs could serve as diagnostic and prognostic biomarkers for patients with CRC (P = 0.0001). Serum levels of miR-194 and miR-29b may serve as potential biomarkers for diagnosis and prognosis of CRC.
微小RNA（miRNA），即miR-194和miR-29b，已证实在结直肠癌（CRC）中表达下调，与对照组相比，其可能有助于识别和分类CRC患者。在本研究中，我们旨在探讨这些miRNA的血清水平是否可能成为CRC诊断和预后的潜在生物标志物。采用定量逆转录聚合酶链反应（qRT-PCR）检测法来测定并比较55例CRC患者和55例对照者血清中miR-194和miR-29b的水平。分析了患者中这些miRNA水平与癌症临床病理分期之间的相关性。分别进行了受试者工作特征（ROC）曲线分析和生存分析，以确定这些miRNA的诊断和预后价值。结果发现，CRC患者血清中miR-194和miR-29b的水平显著低于对照组（P < 0.0001）。此外，患者中这些miRNA的血清水平与TNM晚期分期呈负相关（P = 0.01）。ROC曲线分析和生存分析表明，这些miRNA水平降低可作为CRC患者的诊断和预后生物标志物（P = 0.0001）。血清中miR-194和miR-29b的水平可能是CRC诊断和预后的潜在生物标志物。
